Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Surgical Oncology, Hepato-Pancreato-Biliary Surgery, Houston, TX, USA.
Ann Surg Oncol. 2017 Sep;24(9):2595. doi: 10.1245/s10434-017-5878-3. Epub 2017 May 16.
Surgical resection of all sites of disease, in combination with effective systemic chemotherapy, offers the only potential chance for cure for patients with stage IV colorectal cancer (CRC). Coordinated multistage resection using a minimally invasive approach may provide optimal oncologic outcome while potentially offering the benefit of decreased morbidity.
A 66-year-old women presented with transverse colon cancer and synchronous metastasis (CRLM) in segment IV involving the middle hepatic vein and main left portal pedicle, as well as the left adrenal gland. Due to favorable response to neoadjuvant chemotherapy (FOLFOX/bevacizumab), the patient was considered for resection but developed some obstructive symptoms from the primary tumor, necessitating re-coordination of treatment sequencing from the 'liver-first' approach.
The first procedure combined laparoscopic subtotal colectomy (extracorporeal anastomosis) with left adrenalectomy. After restaging, CRLM was removed separately 2 months later via laparoscopic left hepatectomy extending beyond the middle hepatic vein. Successful completion of the two procedures depended on optimal patient/port positioning for the combined colon/adrenal surgery and the second-stage liver resection. Postoperative lengths of stay were 4 and 3 days, respectively, and were without complication. Adjuvant FOLFOX was initiated 21 days following liver surgery, and the patient has been disease-free for 36 months.
This case illustrates the feasibility of the total laparoscopic approach to multivisceral resection for synchronous stage IV CRC in the context of a preplanned, staged multidisciplinary strategy. This approach may offer optimal cancer management, including early return to systemic therapy, shortened time intervals between stages, and minimal postoperative morbidity.1 3.
对于 IV 期结直肠癌(CRC)患者,通过手术切除所有病变部位并结合有效的全身化疗,是唯一有治愈可能的方法。采用微创方法进行协调的多阶段切除术可能提供最佳的肿瘤学结果,同时可能降低发病率。
一位 66 岁女性,横结肠癌伴同步转移(CRLM),累及 IV 段的肝中静脉和主左门静脉干以及左肾上腺。由于新辅助化疗(FOLFOX/贝伐单抗)有良好的反应,患者被考虑进行切除,但由于原发肿瘤出现一些阻塞症状,需要重新协调治疗顺序,采用“肝优先”方法。
第一阶段手术联合腹腔镜次全结肠切除术(体外吻合)和左肾上腺切除术。重新分期后,2 个月后通过腹腔镜左半肝切除术(延伸至肝中静脉)单独切除 CRLM。两次手术的成功完成取决于合并结肠/肾上腺手术和第二阶段肝切除术的患者/端口最佳定位。术后住院时间分别为 4 天和 3 天,无并发症。肝手术后 21 天开始辅助 FOLFOX,患者无病生存 36 个月。
该病例说明了在预先计划的多学科分期策略的背景下,采用全腹腔镜方法进行同步 IV 期 CRC 多脏器切除的可行性。这种方法可能提供最佳的癌症管理,包括早期恢复全身治疗、缩短各阶段之间的时间间隔以及最小的术后发病率。1 3.